Stockreport

Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.

Lisata Therapeutics, Inc.  (LSTA) 
PDF Each Lisata stockholder to receive $5.00 per share in cash payable at closing plus one contingent value right for a potential additional cash payment of $1.00 per share [Read more]